The Jab: How will science benefit?

The concerted and rapid efforts to counter covid-19 have turbo-charged scientific progress. How can this new knowledge be applied to treat future threats to human health?  Gregg Glenn, head of research and development at Novavax on why that vaccine is effective against variants.  Alok Jha, The Economist's science correspondent, hosts with our health policy editor, Natasha Loder. Oliver Morton, briefings editor, Cuba correspondent Roseanne Lake and James Fransham from our data team join them. For full access to The Economist’s print, digital and audio editions subscribe at economist.com/thejabpod. Sign up for our new weekly science and data newsletters at economist.com/simplyscience and economist.com/offthecharts   Hosted on Acast. See acast.com/privacy for more information.

Om Podcasten

The Economist unlocks the science, data and politics behind the most ambitious inoculation programme the world has ever seen.Alok Jha, The Economist’s science correspondent, hosts with Natasha Loder, our health-policy editor. Each week our reporters and data journalists join them in conversation, along with scientists around the world.Sign up for Economist Podcasts+ at www.economist.com/podcastsplusIf you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription. Hosted on Acast. See acast.com/privacy for more information.